First results from the dose escalation part of the phase 1 study of KTX1001, an oral, first-in-class, potent inhibitor of MMSET/NSD2 for relapsed/refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Bories, P.; Gasparetto, C.; Dingli, D.; Lonial, S.; Usmani, S. Z.; Berdeja, J. G.; Chung, A.; Afrough, A.; Rosiñol, L.; Yee, A. J.; Trudel, S.; Siegel, D. S.; Rodríguez-Otero, P.; Bang, S.; Connolly, T.; Lewis, C. A.; Flynt, E.; Vazquez, J.; Miskin, S. U.; Winograd, B.; Mateos, M. V.; Touzeau, C.; Roy, V. |
| Abstract Title: | First results from the dose escalation part of the phase 1 study of KTX1001, an oral, first-in-class, potent inhibitor of MMSET/NSD2 for relapsed/refractory multiple myeloma (RRMM) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 3371 |
| Language: | English |
| ACCESSION: | WOS:001412651600032 |
| DOI: | 10.1182/blood-2024-199174 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
